Next Article in Journal
Recent Advances in the Application of the Antimicrobial Peptide Nisin in the Inactivation of Spore-Forming Bacteria in Foods
Previous Article in Journal
Oxidative C-H/C-H Coupling of Dipyrromethanes with Azines by TiO2-Based Photocatalytic System. Synthesis of New BODIPY Dyes and Their Photophysical and Electrochemical Properties
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Production of 6-l-[18F]Fluoro-m-tyrosine in an Automated Synthesis Module for 11C-Labeling

by
Viktoriya V. Orlovskaya
1,†,
Austin S. Craig
2,3,†,
Olga S. Fedorova
1,
Olga F. Kuznetsova
1,
Bernd Neumaier
2,3,4,*,
Raisa N. Krasikova
1,* and
Boris D. Zlatopolskiy
2,3,4
1
N.P.Bechtereva Institute of the Human Brain, 197376 St. Petersburg, Russia
2
Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
3
Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, 50937 Cologne, Germany
4
Max Planck Institute for Metabolism Research, 50931 Cologne, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2021, 26(18), 5550; https://doi.org/10.3390/molecules26185550
Submission received: 5 August 2021 / Revised: 2 September 2021 / Accepted: 6 September 2021 / Published: 13 September 2021

Abstract

:
6-l-[18F]Fluoro-m-tyrosine (6-l-[18F]FMT) represents a valuable alternative to 6-l-[18F]FDOPA which is conventionally used for the diagnosis and staging of Parkinson’s disease. However, clinical applications of 6-l-[18F]FMT have been limited by the paucity of practical production methods for its automated production. Herein we describe the practical preparation of 6-l-[18F]FMT using alcohol-enhanced Cu-mediated radiofluorination of Bpin-substituted chiral Ni(II) complex in the presence of non-basic Bu4ONTf using a volatile iPrOH/MeCN mixture as reaction solvent. A simple and fast radiolabeling procedure afforded the tracer in 20.0 ± 3.0% activity yield within 70 min. The developed method was directly implemented onto a modified TracerLab FX C Pro platform originally designed for 11C-labeling. This method enables an uncomplicated switch between 11C- and 18F-labeling. The simplicity of the developed procedure enables its easy adaptation to other commercially available remote-controlled synthesis units and paves the way for a widespread application of 6-l-[18F]FMT in the clinic.

1. Introduction

Assessing the metabolic activity of l-aromatic amino acid decarboxylase (AADC) [1] with 6-l-[18F]fluoro-3,4-dihydroxyphenylalanine (6-l-[18F]FDOPA) PET is widely used for the diagnosis and staging of Parkinson’s disease (PD). In patients with PD, the activity of AADC in the striatum is reduced to 5–20% of normal levels before cardinal motor symptoms become apparent [2]. However, kinetic modeling and quantification of 6-l-[18F]FDOPA uptake is complicated by its peripheral metabolism mediated by catechol O-methyltransferase (COMT). The resulting metabolite, 3-O-methyl-[18F]FDOPA, crosses the blood–brain barrier (BBB) and contributes to an undesirable background uptake into the brain, thereby reducing the signal-to-background ratio for 6-l-[18F]FDOPA. To address this problem, an alternative non-catechol radiotracer 6-l-[18F]fluoro-m-tyrosine (6-l-[18F]FMT) has been developed as a suitable substrate for AADC, which is simultaneously no substrate for COMT-mediated O-methylation [3,4]. Due to increased signal-to-noise ratio in the regions of interest, 6-l-[18F]FMT demonstrates higher sensitivity compared to 6-l-[18F]FDOPA and enables a better quantification of AADC levels and activities [5,6,7,8]. While 6-l-[18F]FMT PET has been widely used in rodents and nonhuman primate models of PD [4,6,9,10], only a few applications in human studies have been reported [5,8,11,12]. The clinical application of this radiotracer is significantly limited by the absence of practical automated production methods that could provide the tracer in Curie-level amounts.
Until recently, 6-l-[18F]FMT has been most commonly prepared via electrophilic fluorodemetalation of a commercially available stannylated precursor (N-trifluoroacetyl-3-acetoxy-6-trimethylstannyl-l-phenylalanine ethyl ester) with [18F]F2. The subsequent purification of the radiolabeled intermediate by flash chromatography on alumina, followed by its hydrolysis and semi-preparative HPLC purification, afforded 6-l-[18F]FMT in 17% radiochemical yield [13] (RCY) [14]. Comparable RCYs were reported if bis-N,O-Boc protected precursor was applied [15]. Despite the apparent simplicity and adaptability to automated synthesis modules, electrophilic radiofluorination methods have several limitations, including difficulties to manipulate gaseous [18F]F2, insufficient productivity of gas targets and low molar activities (Am) of the final product owing to unavoidable dilution with 19F [16].
In contrast, radiosyntheses with easily accessible no-carrier-added nucleophilic [18F]fluoride lack these disadvantages and could furnish large quantities of radiofluorinated tracers. Unfortunately, preparation of 18F-labeled aromatic amino acids ([18F]FAAs) lacking an electron-withdrawing group in the phenyl ring using conventional SnAr radiofluorination is challenging. Therefore, 18F-fluorination strategies typically require multistep syntheses starting from 18F-labeling of substituted benzaldehyde with an appropriate leaving group, followed by a series of transformations to build up the target radiolabeled aromatic amino acid. The most successful phase-transfer catalytic (PTC) asymmetric synthesis [17,18,19], particularly valuable for 6-l-[18F]FDOPA, involved five synthesis steps. The key step consisting of alkylation of a suitable glycine equivalent in the presence of a chiral phase transfer catalyst could be carried out with high stereoselectivity resulting in high enantiomeric purity of the desired [18F]FAA tracer. This approach has also been recently applied for the production of 6-l-[18F]FMT [10]. Despite the high enantiomeric purity of the resulting products and reasonable RCYs of up to 35%, there are still concerns about the complexity of this procedure and in some cases the limited stability of starting materials [20].
Alternatively, a three-step nucleophilic labeling method utilizing isotopic 19F/18F exchange in a formyl-activated aromatic amino acid derivative, followed by Baeyer–Villiger oxidation and acid hydrolysis, has been disclosed recently [21]. This method, originally developed for the synthesis of 6-l-[18F]FDOPA, has been evaluated on a small scale for the preparation of 6-l-[18F]FMT [22]. Fair RCYs of 8–13% and cumbersome precursor synthesis limited the practical applications of this method.
The most recent approaches for 18F-labeling of non-activated aromatics rely upon “late-stage radiofluorinations” using a two-step sequence of reactions: radiofluorination of appropriate precursors (iodonium salts, iodonium ylides, nickel complexes, organoborons or stannanes) followed by acid hydrolysis [23]. Among the methods reported, radiofluorination of the appropriate spirocyclic iodonium(III)ylide 1 (Figure 1A) afforded the radiotracer in 18% activity yield (AY) [13] within a synthesis time of ca. 60 min [24]. However, this approach was applied only on a small scale (20–60 MBq) and was not further translated into large-scale automated production. Alternatively, radiofluorination of the appropriate Ni complex precursor 2 (Figure 1B) in the presence of a hypervalent iodine(III) salt afforded 6-l-[18F]FMT in 5% RCY within 60 min [25]. Unfortunately, a pronounced instability of the applied oxidant precludes wider application of this protocol.
Cu-mediated radiofluorination of pinacol arylboronates (ArylBPin) [26] using commercially available Cu(py)4(OTf)2 has been found to be particularly advantageous for the preparation of a wide range of radiotracers [27]. The selection of the salt (or PTC/base combination) for 18F preprocessing is known to have a profound impact on the outcome of base-sensitive Cu-mediated radiofluorinations [28]. Thus, in the first adaptation of this approach for the automated preparation of 6-l-[18F]FMT from precursor 3 (Figure 1C) [29], the conventional [18F]KF/K2CO3/Kryptofix 222 (K222) complex was replaced with a less basic [18F]KF/K2C2O4/K2CO3/K222 combination. Disadvantageously, boiling concentrated HI was applied for the deprotection step. This reagent is extremely corrosive and requires replacement of capillary connections and valves after each production. The remotely controlled synthesis on a Synthra platform afforded 6-l-[18F]FMT in 10% AY within 140 min (Table 1, entry 1). Additionally, repetitive azeotropic drying with MeCN was required to completely remove water. This time-consuming procedure is associated with radioactivity losses owing to radioactive decay and unavoidable heating-induced adsorption of [18F]fluoride on reactor walls. In recent years, several groups suggested protocols obviating azeotropic drying for Cu-mediated fluorination which apply solutions of weakly or non-basic organic salts in suitable protic or aprotic solvents [30,31,32]. Among them, the procedure for alcohol-enhanced Cu-mediated radiofluorination, which consists of the direct elution of 18F with tetraalkylammonium or phosphonium salts in nBuOH into a solution of Cu mediator and precursor in DMA followed by brief heating of the resulting mixture [30] under air, has found broad application for radiolabeling of various substrates. The modification of this procedure (elution of 18F with methanolic Et4NHCO3 followed by removal of low boiling MeOH and Cu-mediated radiofluorination in nBuOH/DMA medium under air) [33] was applied for the preparation of 6-l-[18F]FMT from the Ni complex 4 (Figure 1D) [34]. This crystalline precursor, which contains a Ni-BPB auxiliary as an easily removable dual-protecting group functionality, is readily accessible on a multi-gram scale and can be handled without special precautions. Less corrosive 37% HCl was used for the decomposition of the radiolabeled Ni complex intermediate. Whereas the procedure was highly efficient for the manual synthesis of the radiolabeled amino acid (15 ± 3% AY), its implementation for the automated production of 6-l-[18F]FMT was less satisfactory (6 ± 5% RCY) (Table 1, entry 2).
In this work, we describe a novel procedure for the automated production of 6-l-[18F]FMT based on the modified protocol for alcohol-enhanced Cu-mediated radiofluorination. The latter employs Bu4NOTf as non-basic PTC and low-boiling iPrOH/MeCN mixture as reaction medium.

2. Results and Discussion

2.1. Optimization of the Manual 6-l-[18F]FMT Radiosynthesis

6-l-[18F]FMT was produced as outlined in Scheme 1.
Based on our previous findings [32], we tested to replace the weak base Et4NHCO3 in high boiling nBuOH with non-basic Bu4NOTf in lower boiling iPrOH for elution of [18F]fluoride. Application of the “back-flushing” protocol [25] enabled >90% 18F recovery (n > 30). [18F]Fluoride was directly eluted into a solution of 4 and Cu mediator, avoiding any evaporation steps.
Initially, the radiofluorination step was carried out in iPrOH/DMA using 15 µmol precursor and 7.5 µmol Cu mediator as described previously [32]. Despite high 18F incorporation rates (>80% by radioTLC), we were faced with incomplete hydrolysis of the intermediary radiolabeled complex 5 if HCl was directly added to the reaction mixture. Furthermore, concentrated HCl was required to achieve reasonable (>50%) RCYs of 6-l-[18F]FMT (determined by HPLC). 37% HCl is rather corrosive and not well compatible with the components of automated modules. Concentration of the reaction mixture could simplify the hydrolysis/deprotection step and enable the application of diluted HCl. In order to facilitate solvent removal, we replaced DMA with highly volatile MeCN. This modification required a reassessment of radiolabeling conditions. Accordingly, the highest RCYs of 5 were obtained using 10 µmol of radiolabeling precursor and 16 µmol Cu(py)4(OTf)2, respectively, in 27% MeCN in iPrOH (1.1 mL). After the reaction mixture was heated to 90 °C for 15 min, all volatiles were removed at 100 °C under a flow of N2 within 3–4 min. Finally, the product was released using a mixture of aqueous HCl/MeOH; MeOH was added to homogenize the reaction mixture.
Several conditions for decomposition of 5 were tested. Heating of 1.5 n HCl in 50% MeOH (1 mL) led to the fast and complete hydrolysis of the 18F-fluorinated intermediate. Unfortunately, up to 36% of an unidentified labeled byproduct was observed in this case (Figure 2B, Block I in Supplementary Materials). Application of 0.5 n HCl in the same solvent allowed us to suppress the formation of this byproduct to 12% (Figure 2C). Lower acid concentration was not sufficient to completely deprotect/decompose 5. Notably, 6-l-[18F]FMT was efficiently separated from the impurity by semi-preparative HPLC.

2.2. Automated Production of 6-l-[18F]FMT

One of the decisive factors for a fast, successful implementation of radiosynthesis into a remotely controlled module is the simplicity of the initial preparation procedure. Accordingly, we implemented a very simple setup for the preparation of 6-l-[18F]FMT by Cu-mediated radiofluorination: pre-loading of the reactor vial with a solution of radiolabeling precursor and Cu mediator in the reaction solvent followed by the elution of [18F]fluoride directly into the reaction vessel, heating of the reaction mixture, and hydrolysis of the radiolabeled intermediate 5 in the same vessel. For the purpose of this study we modified a TRACERlab FX C Pro synthesis module (GE Healthcare, Waukesha, WI, USA) developed for 11C-labeling using gaseous radiolabeled precursors, such as [11C]CO2 and [11C]CH4, which is underutilized in our lab owing to the steadily increasing demand of 18F-labeled compounds compared to 11C-labeled tracers. Accordingly, the modified module configuration with additional components (valves, luer adapters, etc.) enabled us to carry out [18F]fluoride preprocessing. The module was originally equipped with a small 2 mL reaction vessel, compared with the standard 20 mL reactor in modules commonly used for nucleophilic radiofluorinations such as the TRACERlab FX N Pro. Therefore, the amounts of solvents had to be adjusted to carry out both fluorination and hydrolysis in the small reactor. All parameters optimized for the manual radiosynthesis were used in the automated tracer production without further modifications. Notably, radiofluorination proceeds under nitrogen instead of air usually applied for Cu-mediated 18F-fluorination of boronate and stannyl substrates [26]. This could be advantageous if the module is used also for the production of other PET tracers which require inert conditions.
For the isolation of 6-l-[18F]FMT, the HPLC system, originally available on the GE Tracerlab FX C Pro module, was used without any modifications.
The AY of 6-l-[18F]FMT was 20 ± 3% (n = 3), within a total synthesis time of 70 min comprising purification and formulation. The radiotracer was obtained in a radiochemical purity (Figure 3B, Block II in Supplementary Materials) and enantiomeric purity (Figure 4B, Block III in Supplementary Materials) of >99% and molar activities of 125–250 GBq/µmol (EOS) (Block IV in Supplementary Materials). The residual copper and nickel contents, measured by ICP/MS, were less than 0.05 ppm and 0.004 ppm, respectively. These values were below any level of concern according to the ICH Guideline of Elemental Impurities (Q3D) [35]. The amount of residual Bu4N salts was below the detection limit of the applied HPLC method. In the corresponding UV chromatogram, no peak with a Rt of 5.6 min, which corresponds to Bu4N+, was observed (Figure 3C).

3. Experimental

3.1. Materials and Methods

Unless otherwise stated, reagents and solvents were commercially available and used without further purification. Anhydrous acid-free MeCN (max 10 ppm H2O) was purchased from Kriochrom, Russia. The precursor for 6-l-[18F]FMT, (S,S)-Ni-BPB-2-Bpin-5-MOMO-Phe (4, Figure 1), was prepared according to [34]; the reference standard of 6-dl-FMT was obtained from Merck. Deionized water (18.2 MΩ*cm) from an in-house Millipore Simplicity purification system was used for the preparation of all aqueous solutions. [18O]H2O (97% enrichment) was purchased from Global Scientific Technologies, Russia. Sep-Pak Accell Plus QMA Plus Light Cartridges (130 mg) were acquired from Waters Corporation, Millford, CT, USA and were conditioned with 10 mL of 0.05 m NaHCO3 followed by 10 mL H2O before application.
Radio-TLC analyses were carried out on silica gel plates (60 F254, Merck or Sorbfil, Lenchrom, Russia); radioactivity distribution was determined using radioTLC scanner miniGita (Raytest, Straubenhardt, Germany) or Scan-RAM radioTLC scanner controlled by the chromatography software package Laura for PET (LabLogic, Sheffield, UK). An aliquot of the crude reaction mixture (2–3 μL) was applied onto a TLC plate, and the plate was then developed in EtOAc/CHCl3/AcOH (4/1/1); the Rf values for [18F]F and 18F-labeled intermediate 5 amounted to 0.05 and 0.83, respectively. The radiochemical conversion (RCC) was defined as the ratio of the product peak area to total peak area on the TLC; the RCC value was not corrected for decay. Radiochemical purity of 6-l-[18F]FMT (Rf 0.70) was determined using MeOH/AcOH (9/1) as an eluent.
The analytical HPLC system ICS-5000 (Dionex, Sunnyvale, CA, USA) consisted of a gradient pump, Rheodyne-type injector with a 20 μL loop and variable wavelength UV absorbance detector (set to 254 nm) connected in series with a radiodetector (Carrol and Ramsey Associates model 105-S). HPLC analytics: column: XBridge® C18 5 µm, 150 × 4.6 mm (Waters, Millford, CT, USA); gradient: 0–2 min: 2% MeCN (0.1% TFA), 2–13 min: 2–90% MeCN (0.1% TFA); flow rate: 2.0 mL/min.
The UV and radioactivity detectors were connected in series resulting in a delay of 0.1 min. The Rt values of 5 and 6-l-[18F]FMT were 10.3 and 4.5 min, respectively. Bu4NOTf content in the final product was determined using the same conditions; Rt (Bu4N+): 5.6 min. Enantiomeric purity of 6-l-[18F]FMT was determined using the following conditions: column: Chirobiotic T 150 × 4.6 mm (Astec, Whippany, NJ, USA); eluent: 10% EtOH in 0.1% Et3NOAc; flow rate: 1.0 mL/min. Rt values for l- and d-isomers of FMT were 4.3 and 5.4 min, respectively. Ni and Cu content in the final formulation was determined by ICP-MS using ICP Optical Emission Spectrometer Varian 725-ES (Varian, Palo Alto, CA, USA).
6-l-[18F]FMT was isolated using the HPLC package available on GE Tracerlab FX C Pro module (GE Healthcare, Waukesha, WI, USA), consisting of a SYCAM S1122 pump, UV detector KNF, LAB LABOPORT, 2 mL injection loop and β-radioactivity flow detector. Conditions: column: C18 amide, 250 × 10 mm, 5 µm (Supelco, Bellefonte, PA, USA) equipped with a guard column (Security Guard Cartridge AJO-8327-S in Guard Cartridge Holder KJO-4282, Phenomenex, Torrance, CA, USA); eluent: 0.1% AcOH; flow rate: 4 mL/min; Rt for 6-l-[18F]FMT: ~12 min.

3.2. Production of [18F]Fluoride

[18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction by irradiation of [18O]H2O (97% enrichment, Global Scientific Technologies, Sosnovyj Bor, Russia) in a Ag target (1.4 mL) with 16.4 MeV protons at a PETtrace 4 cyclotron (GE Healthcare, Uppsala, Sweden). The irradiated [18O]H2O was transferred from the target using a flow of helium and loaded onto a Sep-Pak Accell Plus QMA Plus Light Cartridge (130 mg). The luer-lock fitting of the cyclotron delivery line was connected to the male side of the cartridge.

3.3. Manual Radiosynthesis of 6-l-[18F]FMT

A QMA cartridge loaded with [18F]fluoride (7–15 GBq) was washed with iPrOH (3 mL) from the male side and dried with nitrogen gas for 2 min. Afterwards, 18F was eluted from the resin backwards relative to the loading direction with a solution of Bu4NOTf (5 mg, 12.5 µmol) in iPrOH (0.8 mL) into the 2 mL reaction vessel prefilled with a solution of 4 (7.7 mg, 10 µmol) and Cu(py)4(OTf)2 in MeCN (0.3 mL). The reaction mixture was stirred at 90 °C for 15 min. Thereafter, volatiles were evaporated at 80 °C under N2 flow and the reaction vessel was cooled down to 40 °C. A total of 0.5 n HCl in 50% MeOH (1 mL) was added and the mixture was stirred at 100 °C for 10 min. When hydrolysis was completed (HPLC control), volatiles were removed at 120 °C under N2 flow. The reaction vessel was cooled down to 50 °C, MeOH (0.5 mL) was added and the resulting solution was transferred into the reaction vessel containing 0.1% AcOH (1.4 mL) of a GE Tracerlab FX C Pro module. The content of the vessel (total volume about 1.8–1.9 mL) was loaded into the HPLC loop. The 6-l-[18F]FMT (Rt 12 min) fraction (4–5 mL) was collected through a 0.22 μm filter (Millipore, Burlington, MA, USA) in a vented sterile vial prefilled with sterile saline (5 mL).

3.4. Automated Radiosynthesis of 6-l-[18F]FMT

The commercially available synthesis module TRACERlab FX C Pro (GE Healthcare, Waukesha, WI, USA) was employed after some modifications. This module, primarily designed for 11C-labeling, was modified for radiofluorination with regard to both hardware and software (sequence timings). The modified module, described in Figure 5, was composed of three functional blocks: Block I: preprocessing of [18F]fluoride; Block II: radiosynthesis (radiofluorination and hydrolysis); Block III: HPLC purification and formulation.
The most significant modification of the module configuration was introduced in Block I (Figure 5) for [18F]fluoride preprocessing. For this purpose, additional valves V9, V15 and V16 were installed and integrated into the control program along with two Wheaton vials (5 mL) with screw caps prefilled with iPrOH and QMA eluent (Bu4NOTf in iPrOH). Nitrogen gas for the reagent transfer was supplied via V25 and V29 valves.
Only minor configurational changes were made on the side of the reaction vessel (RV) and HPLC purification system (Blocks II and III). The original 2 mL RV was used for the radiofluorination and hydrolysis/deprotection steps. The amounts of solvents and solutions used in every synthesis step were adjusted to this small volume RV. Synthesis steps and their operation modes are summarized in Table 2.

4. Conclusions

The preparation of 6-l-[18F]FMT using Cu-mediated radiofluorination of Bpin-substituted chiral Ni complex 4 was successfully implemented onto a TRACERlab FX C Pro radiosynthesis module usually designed for 11C-labeling. This easy switch between 18F and 11C labeling could be of high interest owing to the steadily increasing demand for radiofluorinated, compared to 11C-labeled, tracers. Application of non-basic Bu4NOTf for 18F-elution and low boiling mixture iPrOH and MeCN as reaction medium enabled the fast and efficient production of 6-l-[18F]FMT without the need for any intermediary purification and with the single evaporation step. The simplicity of the developed procedure allows its easy adaptation to other commercially available remote-controlled synthesis units and paves the way for widespread application of this important PET radiotracer.

Supplementary Materials

The following are available online: radio-HPLC chromatograms, Block I: Radiofluorination of Bpin-substituted chiral Ni complex 4 and hydrolysis of radiolabeled intermediate [18F]5: radio-HPLC traces of the crude reaction mixtures, Block II: Quality control of 6-l-[18F]FMT (HPLC traces), Block III: Control of enantiomeric purity of 6-l-[18F]FMT, Block IV: Determination of molar activity (Am) of 6-l-[18F]FMT.

Author Contributions

V.V.O., O.F.K., O.S.F., A.S.C. and B.D.Z. performed experiments; B.N., R.N.K. and B.D.Z. conceived and designed experiments; V.V.O., B.N., R.N.K. and B.D.Z. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Deutsche Forschungsgemeinschaft (DFG), grant ZL 65/1-1, and by the state assignment of the Ministry of Education and Science of Russian Federation, theme number 0133-2019-0004.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors thank Alexander Lumpov (V.G. Chlopin Radium Institute, St. Petersburg) for the determination of residual nickel and copper content.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples are not available due to being perishable goods.

References

  1. Kilbourn, M.R. 11C- and 18F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future. Biomedicines 2021, 9, 108. [Google Scholar] [CrossRef]
  2. Nagatsu, T.; Sawada, M. Biochemistry of post-mortem brains in Parkinson’s disease: Historical overview and future prospects. J. Neural Transm. Suppl. 2007, 72, 113–120. [Google Scholar] [CrossRef]
  3. DeJesus, O.T.; Sunderland, J.J.; Nickles, J.R.; Mukherjee, J.; Appelman, E.H. Synthesis of radiofluorinated analogs of m-tyrosine as potential l-dopa tracers via direct reaction with acetylhypofluorite. Int. J. Rad. Appl. Instrum. A 1990, 41, 433–437. [Google Scholar] [CrossRef]
  4. Barrio, J.R.; Huang, S.-C.; Yu, D.-C.; Melega, W.P.; Quintana, J.; Cherry, S.R.; Jacobson, A.; Namavari, M.; Satyamurthy, N.; Phelps, M.E. Radiofluorinated L-m-tyrosines: New in-vivo probes for central dopamine biochemistry. J. Cereb. Blood Flow Metab. 1996, 16, 667–678. [Google Scholar] [CrossRef] [Green Version]
  5. Nahmias, C.; Wahl, L.; Chirakal, R.; Firnau, G.; Garnett, E.S. A probe for intracerebral aromatic amino-acid decarboxylase activity: Distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain. Mov. Disord. 1995, 10, 298–304. [Google Scholar] [CrossRef] [PubMed]
  6. Doudet, D.J.; Chan, G.L.-Y.; Jivan, S.; DeJesus, O.T.; McGeer, E.G.; English, C.; Ruth, T.J.; Holden, J.E. Evaluation of Dopaminergic Presynaptic Integrity: 6-[18F]Fluoro-L-Dopa Versus 6-[18F]Fluoro-L-m-Tyrosine. J. Cereb. Blood Flow Metab. 1999, 19, 278–287. [Google Scholar] [CrossRef] [Green Version]
  7. Eberling, J.L.; Bankiewicz, K.S.; O’Neil, J.P.; Jagust, W.J. PET 6-[18F]fluoro-L-m-tyrosine Studies of dopaminergic function in human and nonhuman primates. Front. Hum. Neurosci. 2007, 1, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Li, C.T.; Palotti, M.; Holden, J.E.; Oh, J.; Okonkwo, O.; Christian, B.T.; Bendlin, B.B.; Buyan-Dent, L.; Harding, S.J.; Stone, C.K.; et al. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa uptake in Parkinson’s disease. Synapse 2014, 68, 325–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. DeJesus, O.; Endres, C.J.; Shelton, S.E.; Nickles, R.J.; Holden, J.E. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: Comparison with 6-fluorodopa. J. Nucl. Med. 1997, 38, 630–636. [Google Scholar] [PubMed]
  10. Becker, G.; Bahri, M.A.; Michel, A.; Hustadt, F.; Garraux, G.; Luxen, A.; Lemaire, C.; Plenevaux, A. Comparative assessment of 6-[18F]fluoro-L-m-tyrosine and 6-[18F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson’s disease rat model. J. Neurochem. 2017, 141, 626–635. [Google Scholar] [CrossRef] [Green Version]
  11. Gallagher, C.L.; Christian, B.T.; Holden, J.E.; Dejesus, O.T.; Nickles, R.J.; Buyan-Dent, L.; Bendlin, B.B.; Harding, S.J.; Stone, C.K.; Mueller, B.; et al. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson’s disease. Mov. Disord. 2011, 26, 2032–2038. [Google Scholar] [CrossRef]
  12. Asari, S.; Fujimoto, K.; Miyauchi, A.; Sato, T.; Nakano, I.; Muramatsu, S. Subregional 6-[18F]fluoro-m-tyrosine uptake in the striatum in Parkinson’s disease. BMC Neurol. 2011, 23, 11–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Coenen, H.H.; Gee, A.G.; Adam, M.; Antoni, G.; Cutler, C.S.; Fujibayashi, Y.; Jeong, J.M.; Mach, R.H.; Mindt, T.L.; Pike, V.W.; et al. Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. J. Label. Comp. Radiopharm. 2018, 61, 3, 402–404. [Google Scholar] [CrossRef] [Green Version]
  14. Namavari, M.; Satyamurthy, N.; Phelps, M.E.; Barrio, J.R. Synthesis of 6-[18F] and 4-[18F]fluoro-L-m-tyrosines via regioselective radio-fluorodestannylation. Appl. Radiat. Isot. 1993, 44, 527–536. [Google Scholar] [CrossRef]
  15. Van Brocklin, H.F.; Blagoev, M.; Hoepping, A.; O’Neil, J.P.; Klose, M.; Schubiger, P.A.; Ametamey, S. A new precursor for the preparation of 6-[18F]Fluoro-l-m-tyrosine ([18F]FMT): Efficient synthesis and comparison of radiolabeling. Appl. Radiat. Isot. 2004, 61, 1289–1294. [Google Scholar] [CrossRef] [PubMed]
  16. Wagner, M.; Wuest, F. The Radiopharmaceutical chemistry of fluorine-18: Electrophilic fluorinations. Radiopharm. Chem. 2019, 285–295. [Google Scholar] [CrossRef]
  17. Libert, L.C.; Franci, X.; Plenevaux, A.R.; Ooi, T.; Maruoka, K.; Luxen, A.J.; Lemaire, C.F. Production at the Curie level of no carrier-added 6-18F-fluoro-L-dopa. J. Nucl. Med. 2013, 54, 1154–1161. [Google Scholar] [CrossRef] [Green Version]
  18. Lemaire, C.; Libert, L.; Franci, X.; Kuci, S.; Giacomelli, F.; Genon, J.-L.; Luxen, A. Automated production at the curie level of no carrier-added 6-[18F]fuoro-L-dopa and 2-[18F]fuoro-L-tyrosine on a FASTlab synthesizer. J. Label. Comp. Radiopharm. 2015, 58, 281–290. [Google Scholar] [CrossRef]
  19. Krasikova, R.N.; Zaitsev, V.V.; Ametamey, S.M.; Kuznetsova, O.F.; Fedorova, O.S.; Mosevich, I.K.; Belokon, Y.N.; Vyskočil, Š.; Shatik, S.V.; Nader, M.; et al. Catalytic enantioselective synthesis of 18F-fluorinated α-amino acids under phase-transfer conditions using (S)-NOBIN. Nucl. Med. Biol. 2004, 31, 597–603. [Google Scholar] [CrossRef]
  20. Pretze, M.; Franck, D.; Kunkel, F.; Foßhag, E.; Wängler, C.; Wängler, B. Evaluation of two nucleophilic syntheses routes for the automated synthesis of 6-[18F]fluoro-l-DOPA. Nucl. Med. Biol. 2017, 45, 35–42. [Google Scholar] [CrossRef]
  21. Wagner, F.M.; Ermert, J.; Coenen, H.H. Three-Step, ‘‘One-Pot’’ Radiosynthesis of 6-fluoro-3,4-dihydroxy-L-phenylalanine by isotopic exchange. J. Nucl. Med. 2009, 50, 1724–1729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Meleán, J.C.; Ermert, C.; Coenen., H.H. A three-step radiosynthesis of 6-[18F]fluoro-L-meta-tyrosine starting with [18F]fluoride. J. Label. Comp. Radiopharm. 2015, 58, 133–140. [Google Scholar] [CrossRef] [PubMed]
  23. Preshlock, S.; Tredwell, M.; Gouverneur, V. 18F-Labeling of arenes and heteroarenes for applications in positron emission tomography. Chem. Rev. 2016, 116, 719–766. [Google Scholar] [CrossRef] [PubMed]
  24. Rotstein, B.H.; Wang, L.; Liu, R.Y.; Patteson, J.; Kwan, E.E.; Vasdev, N.; Liang, S.H. Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides. Chem. Sci. 2016, 7, 4407–4417. [Google Scholar] [CrossRef] [Green Version]
  25. Zlatopolskiy, B.; Zischler, J.; Urusova, E.A.; Endepols, H.; Kordys, E.; Frauendorf, H.; Mottaghy, F.M.; Neumaier, B. A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. Chem. Open 2015, 4, 457–462. [Google Scholar] [CrossRef]
  26. Tredwell, M.; Preshlock, S.M.; Taylor, N.J.; Gruber, S.; Huiban, M.; Passchier, J.; Mercier, J.; Genicot, C.; Gouverneur, V. A general copper-mediated nucleophilic 18F-luorination of arenes. Angew. Chem. Int. Ed. 2014, 53, 7751–7755. [Google Scholar] [CrossRef]
  27. Wright, J.S.; Kaur, T.; Preshlock, S.; Tanzeyl, S.S.; Winton, W.P.; Sharninghausen, L.S.; Wiesner, N.; Brooks, A.F.; Sanford, M.S.; Scott, P.J.H. Copper-mediated late-stage radiofuorination: Five years of impact on preclinical and clinical PET imaging. Clin. Transl. Imaging 2020, 8, 167–206. [Google Scholar] [CrossRef]
  28. Zlatopolskiy, B.D.; Zischler, J.; Krapf, P.; Zarrad, F.; Urusova, E.A.; Kordys, E.; Endepols, H.; Neumaier, B. Copper-Mediated Aromatic Radiofluorination Revisited: Efficient Production of PET Tracers on a Preparative Scale. Chem. Eur. J. 2015, 21, 5972–5979. [Google Scholar] [CrossRef]
  29. Preshlock, S.; Calderwood, S.; Verhoog, S.; Hienzsch, A.; Cailly, T.; Schedler, M.; Mollitor, J.; Hoepping, A.; Genicot, C.; Tredwell, M.; et al. Enhanced copper-mediated 18F-fluorination of aryl boronic esters provides eight radiotracers for PET applications. Chem. Commun. 2016, 52, 8361–8364. [Google Scholar] [CrossRef]
  30. Zischler, J.; Kolks, N.; Modemann, D.; Neumaier, B.; Zlatopolskiy, B.D. Alcohol-Enhanced Cu-Mediated Radiofluorination. Chem. Eur. J. 2017, 23, 3251–3256. [Google Scholar] [CrossRef]
  31. Antuganov, D.; Zykov, M.; Timofeev, V.; Timofeeva, K.; Antuganova, Y.; Fedorova, O.; Orlovskaya, V.; Krasikova, R. Copper-mediated radiofluorination of aryl pinacolboronate esters: A straightforward protocol using pyridinium sulfonates. Eur. J. Org. Chem. 2019, 918–922. [Google Scholar] [CrossRef]
  32. Orlovskaya, V.; Fedorova, O.; Kuznetsova, O.; Krasikova, R. Cu-Mediated Radiofluorination of Aryl Pinacolboronate Esters: Alcohols as Solvents with Application to 6-L-[18F]FDOPA Synthesis. Eur. J. Org. Chem. 2020, 7079–7086. [Google Scholar] [CrossRef]
  33. Zlatopolskiy, B.D.; Zischler, J.; Schäfer, D.; Urusova, E.A.; Guliyev, M.; Bannykh, O.; Endepols, H.; Neumaier, B. Discovery of 7-[18F]Fluorotryptophan as a Novel Positron Emission Tomography (PET) Probe for the Visualization of Tryptophan Metabolism in Vivo. Med. Chem. 2018, 61, 189–206. [Google Scholar] [CrossRef] [PubMed]
  34. Craig, A.; Kolks, N.; Urusova, E.A.; Zischler, J.; Brugger, M.; Endepols, H.; Neumaier, B.; Zlatopolskiy, B.D. Preparation of labeled aromatic amino acids via late-stage 18F-fluorination of chiral nickel and copper complexes. Chem. Commun. 2020, 56, 9505–9508. [Google Scholar] [CrossRef] [PubMed]
  35. ICH Guideline of Elemental Impurities Q3D. Available online: https://database.ich.org/sites/default/files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf (accessed on 22 March 2021).
Figure 1. Preparation of 6-l-[18F]FMT via late-stage radiofluorination with [18F]fluoride. Radiolabeling conditions: (A) (i) azeotropic drying of [18F]Et4NF/Et4NHCO3 (×3), (ii) DMF, 120 °C, 20 min [24]; (B) [18F]KF/K2CO3/18-crown-6, 1,1’-(phenyl-λ3-iodanediyl)bis(4-methoxypyridin-1-ium) trifluoromethanesulfonate, MeCN, r.t., 5 min [25]; (C) (i) azeotropic drying of [18F]KF/K2C2O4/K2.2.2 (×5), (ii) Cu(py)4(OTf)2, DMF, 120 °C, 20 min, air [29]; (D) [18F]Et4NF/Et4NHCO3, Cu(py)4(OTf)2, nBuOH/DMA, 110 °C, 15 min, air [34]. Procedures (B) and (D) avoid any azeotropic drying steps. a—manual synthesis; b—synthesis in a remotely controlled unit. AY—activity yield of the HPLC purified 6-l-[18F]FMT [13]; r.t.—room temperature.
Figure 1. Preparation of 6-l-[18F]FMT via late-stage radiofluorination with [18F]fluoride. Radiolabeling conditions: (A) (i) azeotropic drying of [18F]Et4NF/Et4NHCO3 (×3), (ii) DMF, 120 °C, 20 min [24]; (B) [18F]KF/K2CO3/18-crown-6, 1,1’-(phenyl-λ3-iodanediyl)bis(4-methoxypyridin-1-ium) trifluoromethanesulfonate, MeCN, r.t., 5 min [25]; (C) (i) azeotropic drying of [18F]KF/K2C2O4/K2.2.2 (×5), (ii) Cu(py)4(OTf)2, DMF, 120 °C, 20 min, air [29]; (D) [18F]Et4NF/Et4NHCO3, Cu(py)4(OTf)2, nBuOH/DMA, 110 °C, 15 min, air [34]. Procedures (B) and (D) avoid any azeotropic drying steps. a—manual synthesis; b—synthesis in a remotely controlled unit. AY—activity yield of the HPLC purified 6-l-[18F]FMT [13]; r.t.—room temperature.
Molecules 26 05550 g001
Scheme 1. Radiosynthesis scheme for 6-l-[18F]FMT by Cu-mediated radiofluorination of 4.
Scheme 1. Radiosynthesis scheme for 6-l-[18F]FMT by Cu-mediated radiofluorination of 4.
Molecules 26 05550 sch001
Figure 2. Radio-HPLC analysis of the reaction mixture: (A) radiofluorination of 4 (preparation of 5); (B) hydrolysis of 5 with 1.5 n HCl in 50% MeOH; (C) hydrolysis of 5 with 0.5 n HCl in 50% MeOH. HPLC conditions: column: XBridge® C18 5 µm, 150 × 4.6 mm (Waters, Millford, CT, USA); gradient: 0–2 min: 2% MeCN (0.1% TFA), 2–13 min: 2–90% MeCN (0.1% TFA); flow rate: 2.0 mL/min; Rt of 5: 10.3 min; Rt of 6-l-[18F]FMT: 4.6 min.
Figure 2. Radio-HPLC analysis of the reaction mixture: (A) radiofluorination of 4 (preparation of 5); (B) hydrolysis of 5 with 1.5 n HCl in 50% MeOH; (C) hydrolysis of 5 with 0.5 n HCl in 50% MeOH. HPLC conditions: column: XBridge® C18 5 µm, 150 × 4.6 mm (Waters, Millford, CT, USA); gradient: 0–2 min: 2% MeCN (0.1% TFA), 2–13 min: 2–90% MeCN (0.1% TFA); flow rate: 2.0 mL/min; Rt of 5: 10.3 min; Rt of 6-l-[18F]FMT: 4.6 min.
Molecules 26 05550 g002
Figure 3. Quality control of 6-l-[18F]FMT: (A) 6- dl-FMT, UV trace (λ = 254 nm); (B) 6-l-[18F]FMT, radioactivity trace; (C) 6-l-[18F]FMT, UV trace (λ = 254 nm); (D) injection of the starting eluent (2% MeCN (0.1% TFA)), UV trace (λ = 254 nm); HPLC conditions: column: XBridge® C18 5 µm, 150 × 4.6 mm (Waters, Millford, CT, USA); gradient: 0–2 min: 2% MeCN (0.1% TFA), 2–13 min: 2–90% MeCN (0.1% TFA); flow rate: 2.0 mL/min; Rt of 6-l-[18F]FMT: 4.6 min; (D) blank UV chromatogram at 254 nm. Please, notice that the diffuse peak at 3.8–14.0 min and peaks at 3.9; 4.5; 7.2; 8.1; 9.3; 11.4; and 12.6 min (UV 254 nm) are also visible if the starting eluent is injected under the same chromatographic conditions.
Figure 3. Quality control of 6-l-[18F]FMT: (A) 6- dl-FMT, UV trace (λ = 254 nm); (B) 6-l-[18F]FMT, radioactivity trace; (C) 6-l-[18F]FMT, UV trace (λ = 254 nm); (D) injection of the starting eluent (2% MeCN (0.1% TFA)), UV trace (λ = 254 nm); HPLC conditions: column: XBridge® C18 5 µm, 150 × 4.6 mm (Waters, Millford, CT, USA); gradient: 0–2 min: 2% MeCN (0.1% TFA), 2–13 min: 2–90% MeCN (0.1% TFA); flow rate: 2.0 mL/min; Rt of 6-l-[18F]FMT: 4.6 min; (D) blank UV chromatogram at 254 nm. Please, notice that the diffuse peak at 3.8–14.0 min and peaks at 3.9; 4.5; 7.2; 8.1; 9.3; 11.4; and 12.6 min (UV 254 nm) are also visible if the starting eluent is injected under the same chromatographic conditions.
Molecules 26 05550 g003
Figure 4. Determination of enantiomeric purity of 6-l-[18F]FMT by chiral HPLC: (A) 6-dl-FMT, UV trace (λ = 254 nm); peak 1-6-l-FMT; peak 2-6-d-FMT; (B) 6-l-[18F]FMT, radioactivity trace. HPLC conditions: column Chirobiotic T 150 × 4.6 mm (Astec, Whippany, NJ, USA); eluent: 10% EtOH in 0.1% Et3NOAc; flow rate: 1.0 mL/min.
Figure 4. Determination of enantiomeric purity of 6-l-[18F]FMT by chiral HPLC: (A) 6-dl-FMT, UV trace (λ = 254 nm); peak 1-6-l-FMT; peak 2-6-d-FMT; (B) 6-l-[18F]FMT, radioactivity trace. HPLC conditions: column Chirobiotic T 150 × 4.6 mm (Astec, Whippany, NJ, USA); eluent: 10% EtOH in 0.1% Et3NOAc; flow rate: 1.0 mL/min.
Molecules 26 05550 g004
Figure 5. Schematic diagram of the GE TRACERlab FX-C Pro module modified for the preparation of 6-l-[18F]FMT. A: empty vessel; B: 0.5 n HCl in 50% MeOH (1 mL); C: MeOH (0.5 mL); D: 0.1% AcOH (1.5 mL); RV: 4 (7.7 mg, 10 µmol) and Cu(py)4(OTf)2 (11 mg, 16 µmol) in MeCN (0.3 mL); eluent vial: Bu4NOTf (5 mg, 12.5 µmol) in iPrOH (0.8 mL). RV—reaction vessel (2 mL).
Figure 5. Schematic diagram of the GE TRACERlab FX-C Pro module modified for the preparation of 6-l-[18F]FMT. A: empty vessel; B: 0.5 n HCl in 50% MeOH (1 mL); C: MeOH (0.5 mL); D: 0.1% AcOH (1.5 mL); RV: 4 (7.7 mg, 10 µmol) and Cu(py)4(OTf)2 (11 mg, 16 µmol) in MeCN (0.3 mL); eluent vial: Bu4NOTf (5 mg, 12.5 µmol) in iPrOH (0.8 mL). RV—reaction vessel (2 mL).
Molecules 26 05550 g005
Table 1. Automated production of 6-l-[18F]FMT by Cu-mediated radiofluorination of ArylBPin precursors.
Table 1. Automated production of 6-l-[18F]FMT by Cu-mediated radiofluorination of ArylBPin precursors.
Nr.PrecursorFluorination
Conditions
Hydrolysis/Deprotection ConditionsPrecursor/Cu-Catalyst (µmol)AY (%)Synthesis Time (min);Automation ModeReference
13K222/K2C2O4/
K2CO3
Cu(py)4(OTf)2,
DMF,120 °C,
20 min, air
57% HI,
150 °C,
10 min
20/2210140;
Synthra
[29]
24Et4NHCO3, Cu(py)4(OTf)2,
nBuOH/DMA
110 °C, 15 min, air
12 n HCl
110 °C,
10 min
10/206 ± 590;
Semi-automated
[34]
34Bu4NOTf, Cu(py)4(OTf)2,
iPrOH/MeCN
90 °C, 15 min, N2
1 n HCl/MeOH
100 °C,
10 min
10/1620 ± 370;
TracerLab FX
C Pro (modified)
This work
Table 2. Process sequence for the automated synthesis of 6-l-[18F]FMT using the modified GE Tracerlab FX C Pro module (Figure 5).
Table 2. Process sequence for the automated synthesis of 6-l-[18F]FMT using the modified GE Tracerlab FX C Pro module (Figure 5).
EntryProcessActivated Path/Function
Block I
1Loading of [18F]fluoride onto the QMA cartridgeV9-V15-QMA-V16-waste bottle-V10-V22-Vac
2Washing of QMA cartridge with iPrOH (3 mL)V25-V29-V9-V15-QMA-V16-waste bottle-V10-V22-Vac
3Elution of [18F]fluoride from the cartridge into the RV.V25-V29-eluent vial-V16-QMA-V15-RV-V21-V23
Block II
4Radiofluorination, RV, 90 °C, 15 min stirring-
5Removal of volatiles at 80 °C under N2 flowV18-V1-V7-V8-RV-V21-V23
6Transfer of 0.5 n HCl in 50% MeOH from B to RVV18-V2 -RV-V21-V23
7Hydrolysis, RV, 100 °C, 10 min-
8Removal of volatiles at 120 °C under N2 flowV18-V1-V7-V8-RV-V21-V23
9Transfer of MeOH from C to RV, stirringV18-V3-RV-V21-V23
10Transfer of 0.1% AcOH from D to RV, stirringV18-V4-RV-V21-V23
Block III
11Solution transfer from RV into the V-shaped vesselV2-RV-V8-V7-V24-V-shaped vessel
12Loading the content of V-shaped vessel into HPLC loopV2-RV-V8-V7-V24-V-shaped vessel-V13, Load/Inject
13Collection of the radioactive product in the product vialV14, manual operation
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Orlovskaya, V.V.; Craig, A.S.; Fedorova, O.S.; Kuznetsova, O.F.; Neumaier, B.; Krasikova, R.N.; Zlatopolskiy, B.D. Production of 6-l-[18F]Fluoro-m-tyrosine in an Automated Synthesis Module for 11C-Labeling. Molecules 2021, 26, 5550. https://doi.org/10.3390/molecules26185550

AMA Style

Orlovskaya VV, Craig AS, Fedorova OS, Kuznetsova OF, Neumaier B, Krasikova RN, Zlatopolskiy BD. Production of 6-l-[18F]Fluoro-m-tyrosine in an Automated Synthesis Module for 11C-Labeling. Molecules. 2021; 26(18):5550. https://doi.org/10.3390/molecules26185550

Chicago/Turabian Style

Orlovskaya, Viktoriya V., Austin S. Craig, Olga S. Fedorova, Olga F. Kuznetsova, Bernd Neumaier, Raisa N. Krasikova, and Boris D. Zlatopolskiy. 2021. "Production of 6-l-[18F]Fluoro-m-tyrosine in an Automated Synthesis Module for 11C-Labeling" Molecules 26, no. 18: 5550. https://doi.org/10.3390/molecules26185550

Article Metrics

Back to TopTop